Search

Your search keyword '"Travert F"' showing total 201 results

Search Constraints

Start Over You searched for: Author "Travert F" Remove constraint Author: "Travert F"
201 results on '"Travert F"'

Search Results

1. Collaborateurs de la précédente édition

2. Collaborateurs de la présente édition

3. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

7. Indications thérapeutiques et effets métaboliques de la métréleptine chez les patients atteints de lipodystrophie : données de vie réelle du registre français

9. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial

11. Liste des collaborateurs

12. Liste des collaborateurs

13. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

20. Liraglutide and Renal Outcomes in Type 2 Diabetes

21. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOSSuggests an at-risk type 2 diabetes frail patient phenotype

30. One‐year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes

32. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

33. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

35. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

36. Colaboradores de la edición actual

37. Colaboradores de la edición anterior

38. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

39. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

42. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

46. P1085 Impact et rôle du liraglutide, un analogue du GPL-1 humain, dans le diabète de type-2 : le rationnel et le design de l’étude LEADER® évaluant les paramètres cardiovasculaires

47. O67 Comment évaluer la masse bêta-cellulaire résiduelle chez les patients diabétiques de type 1 ? L’Étude ImMaDiab

49. O49 Effet du traitement par leptine recombinante sur l’insulino-sécrétion des patients atteints de syndromes lipodystrophiques

Catalog

Books, media, physical & digital resources